Verluma Market Report 2026

Verluma Market Overview

• The Verluma market growth in the historic period has been driven by advancements in nuclear imaging technologies, increased prevalence of colorectal and solid tumors • Market expansion is supported by growing demand for personalized cancer diagnostics, rising investments in nuclear medicine facilities • Growth Driver: Increasing Incidence Of Cancer Driving Growth In The Market • North America was the largest region in 2025.

What Is Covered Under Verluma Market?

Verluma is a radiolabeled monoclonal antibody fragment used in nuclear medicine to target carcinoembryonic antigen (CEA), a protein often overexpressed in cancerous tumors. It helps detect and stage cancers, such as colorectal cancer, by binding to CEA-expressing tumor cells, allowing visualization through imaging techniques like SPECT. The main types of indications for verluma are cancer and non-cancer. Cancer is a group of diseases characterized by uncontrolled cell growth and the potential to spread, with treatments such as verluma targeting specific cancer cells to reduce tumor growth and improve patient outcomes. It is distributed through various channels such as hospital pharmacies and online pharmacies and are cater to various end users including adult and geriatric.

What Is The Verluma Market Growth Forecast?

The growth in the forecast period can be attributed to growing demand for personalized cancer diagnostics, rising investments in nuclear medicine facilities, expansion of companion diagnostics in oncology, increased use of molecular imaging in cancer staging, ongoing innovation in radiolabeled antibody fragments. Major trends in the forecast period include growing adoption of targeted radiolabeled diagnostics, increasing use of cea-targeted imaging agents, rising demand for early cancer detection tools, expansion of nuclear medicine imaging applications, strengthening integration of precision oncology diagnostics.

Global Verluma Market Segmentation

1) By Indication: Cancer, Non-Cancer 2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Verluma Market?

The increasing incidence of cancer is expected to propel the growth of the verluma market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade surrounding tissues and potentially spread to other body parts through the blood and lymph systems. The rising cancer incidence is due to aging populations, lifestyle changes, and globalization of risk factors. Verluma is a therapeutic device that uses advanced technology, such as electromagnetic fields or other non-invasive methods, to potentially assist in cancer treatment by targeting and disrupting cancer cell growth, promoting healing, and improving the body's response to other therapies. For instance, in 2024, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, around 313,510 new cases of breast cancer were diagnosed, an increase compared to 300,590 cases reported in 2023. Therefore, the increasing incidence of cancer is driving the growth of verluma industry. The increasing demand for diagnostic imaging procedures is expected to propel the growth of the verluma market going forward. Diagnostic imaging procedures refer to various medical techniques used to create visual representations of the interior of a body for clinical analysis and medical intervention. The demand for diagnostic imaging procedures is rising due to the growing prevalence of chronic diseases, an increasing focus on early detection and preventive healthcare, and increased access to healthcare. Verluma improves diagnostic imaging procedures by enhancing image quality through advanced algorithms, enabling more accurate detection and analysis of medical conditions and improving patient outcomes. For instance, in November 2023, according to the National Health Service, a UK-based government department, in the year ending March 2023, England recorded 45.0 million imaging tests, reflecting a 2.2% increase compared to 44.0 million in 2022. Therefore, the increasing demand for diagnostic imaging procedures is driving the growth of the verluma industry. The rise in healthcare expenditure is expected to propel the growth of the verluma market going forward. Healthcare expenditure refers to the total financial resources spent on healthcare services, including medical treatments, hospital care, pharmaceuticals, healthcare infrastructure, and preventive services. The rise in healthcare expenditure is attributed to factors such as an aging population, increasing prevalence of chronic diseases, advancements in medical technologies, and higher demand for healthcare services. Healthcare expenditure benefits Verluma by increasing demand for advanced healthcare technologies, including solutions that improve patient outcomes and operational efficiencies, as healthcare providers invest in innovative tools and systems. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency reported that provisional estimates show UK healthcare spending reached £317 billion in 2024, growing 6.5% nominally and 2.4% in real terms from 2023. Total long-term care expenditure rose 3.1% in real terms in 2023, primarily due to increased government spending. Therefore, the rise in healthcare expenditure is driving the growth of the verluma industry.

Key Players In The Global Verluma Market

Major companies operating in the verluma market are Boehringer Ingelheim International GmbH

Regional Insights

North America was the largest region in the verluma market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Verluma Market?

The verluma market consists of sales of verluma injection and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Verluma Market Report 2026?

The verluma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the verluma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.